Evaluation of a new Apolipoprotein(a) isoform-independent assay for serum Lipoprotein(a)

Molecular and Cellular Biochemistry

Volumn 207, Issue 1-2, 2000, Pages 149-155

  Dembinski, Tom ^a,b   Nixon, Pat ^a   Shen, Garry ^a   Mymin, David ^a   Choy, Patrick C ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Apolipoprotein(a); Enzyme linked immunoassay; Isoforms; Lipoprotein(a); Lipoproteins; Risk factors

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RELIABILITY; RISK ASSESSMENT; RISK FACTOR;

EID: 0034096283     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1007079223546     Document Type: Article

References (23)

1. Marcovina SM, Morrisett JD: Structure and metabolism of lipoprotein(a). Curr Opin Lipidol 6: 136-145, 1995
2. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM: cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 300: 132-137, 1987
3. Liu AC, Lawn RM: Vascular interactions of lipoprotein(a). Curr Opin Lipidol 5: 269-273, 1994
4. Scanu AM, Lawn RM, Armstrong EC: Serum cholesterol levels in human atherosclerosis. Ann Int Med 115: 209-218, 1991
5. Uterman G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E: Defects in the Low Density Lipoprotein Receptor Gene affect Lipoprotein(a) Levels. Multiplicative Interaction of Two Gene Loci Associated with Premature Atherosclerosis. Proc Natl Acad Sci USA 86: 4171-4174, 1989
6. Kamboh MI, Ferrell RE, Kottke BA: Expressed Hypervariable Polymorphism of Apolipoprotein(a). Am J Hum Gen 49: 1063-1074, 1991
7. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ: Identification of 34 Apolipoprotein(a) Isoforms: Differential Expression of Apolipoprotein(a) Alleles between American Blacks and Whites. Biochem Biophys Res Commun 191: 1192-1196, 1993
8. Gonzalez-Gronow M, Edelberg JM, Pizzo SV: Further Characterization of the Cellular Plasminogen Binding Site: Evidence that Plasminogen 2 and Lipoprotein(a) compete for the Same Site. Biochem 28: 2374-2377, 1989
9. Kostner GM: The Physiological Role of Lp(a). In: A. Scanu (ed). Lipoprotein(a). Academic Press, New York, 1990, pp 183-204
10. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 44: 2301-2306, 1998
11. Tate JR, Rifai N, Berg K, Couderc R, Dati F, Kostner GM, Sakurabayashi I, Steinmetz A: International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem 44: 1629-1640, 1998
12. Kostner GM: Standardization of Lp(a) assays [Letter]. Clin Chim Acta 211: 191-194, 1992
13. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP: Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 41: 246-255, 1995
14. Levine DM, Gordon BR: Lipoprotein(a) levels in patients receiving renal replacement therapy: methodologic issues and clinical implications. Am J Kidney Dis 26:162-169, 1995
15. Taddei-Peters WC, Butman BT, Jones GR, Venetta TM, Macomber PF, Ranson JH: Quantification of Lipoprotein (a) Particles Containing Various Apo-lipoprotein(a) Isoforms by a Monoclonal Anti-Apo (a) Capture Antibody and a Polyclonal Anti-Apolipoprotein B Detection Antibody Sandwich Enzyme Immunoassay. Clin Chem 39: 1382-1389, 1993
16. Marz W, Siekmeier R, Kostner GM: Determination of lipoprotein(a): evaluation of three methods. Eur J Clin Chem Clin Biochem 31: 295-301, 1993
17. Shen GX, Mymin D, Dembinski T, Krahn A, Angel A: Polymorphism and Peripheral Levels of Apolipoprotein (a) in Polygenic Hypercholesterolemia and Combined Hyperlipidemia. Clin Invest Med 18: 33-41, 1995
18. rd edition 1994, Oxford Blackwell Scientific Publications, Cambridge, UK, pp 312-333
19. Dembinski TC, Nixon P, Mymin D, Angel A, Ren S, Shen GX. Dramatic Reduction in Serum Lipoprotein (a) by Niacin: Case Report. Clin Biochem 27: 202-203, 1994
20. Koltringer P, Jurgens G. A Dominant Role of Lipoprotein (a) in the Investigation and Evaluation of Parameters Indicating the Development of Cervical Atherosclerosis. Atherosclerosis 58: 187-198, 1985
21. Taddei-Peters WC, Jürgens G, Wiklund O, Költringer P, Petek W, Linden T, Chen Q, Greilberger J, Ullström C. Macomber PF, Butman BT, Ransom JH: ELISA quantitation of Lp(a) concentration demonstrates that Lp(a) is an important risk factor in cerebro- and cardiovascular disease. The FASEB Journal 10: A746, 1996
22. Jürgens G, Taddei-Peters WC, Költringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BT, Stead AG, Ransom JH: Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 26: 1841-1848, 1995
23. Schaeter EJ, Ordovas JM, DeLuca C, D'Agostino RB, Wolf PA, Taddei-Peters W, Butman BT, Ransom JH, Silberman SR, Wilson PWF: Lipoprotein(a) coronary heart disease and carotid artery atherosclerosis in the Framingham Heart Study. Clin Chem 43: S267, 1997